Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

BACKGROUND: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-term outcomes and test whether combining enzalutami...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet Oncol
Egile Nagusiak: Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Sachdeva, Ashwin, Jones, Craig, Hoyle, Alex, Cross, William, Jones, Robert J, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Gilson, Clare, Rush, Hannah, Abdel-Aty, Hoda, Amos, Claire L, Murphy, Claire, Chowdhury, Simon, Malik, Zafar, Martin Russell, J, Parkar, Nazia, Pugh, Cheryl, Diaz-Montana, Carlos, Pezaro, Carmel, Grant, Warren, Saxby, Helen, Pedley, Ian, O’Sullivan, Joe M, Birtle, Alison, Gale, Joanna, Srihari, Narayanan, Thomas, Carys, Tanguay, Jacob, Wagstaff, John, Das, Prantik, Gray, Emma, Alzouebi, Mymoona, Parikh, Omi, Robinson, Angus, Montazeri, Amir H, Wylie, James, Zarkar, Anjali, Cathomas, Richard, Brown, Michael D, Jain, Yatin, Dearnaley, David P, Mason, Malcolm D, Gilbert, Duncan, Langley, Ruth E, Millman, Robin, Matheson, David, Sydes, Matthew R, Brown, Louise C, Parmar, Mahesh K B, James, Nicholas D
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2023
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7616864/
https://ncbi.nlm.nih.gov/pubmed/37142371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(23)00148-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak